Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin and Pembrolizumab in High Grade Upper Tract Urothelial Cancer
NCT05656235Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2024
- Primary completion
- Jun 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin, pembrolizumab in upper tract urothelial carcinoma (UTUC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 2024; status: recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT05656235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656235.